Zan Fleming

Dr. G. Alexander Fleming (Zan), M.D is a well-recognized authority in the metabolic and endocrine fields with extensive U.S. Food and Drug Administration (FDA) experience, where he headed clinical review of drugs for diabetes and other metabolic indications from 1986-98. He led landmark approvals of metformin, the first statin, insulin analogs, and new growth hormone indications. He also represented FDA at the International Conference on Harmonization (ICH), was assigned to World Health Organization (WHO) 1992-93, was responsible for professional education and training in the Center for Drugs Evaluation and Research, and was a major contributor to FDA’s Good Review Practice initiative.